<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124191">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01665573</url>
  </required_header>
  <id_info>
    <org_study_id>120303009906</org_study_id>
    <nct_id>NCT01665573</nct_id>
  </id_info>
  <brief_title>Cannabinoid Augmentation of Fear Response in Humans</brief_title>
  <official_title>Cannabinoid Augmentation of Fear Response in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind, randomized, controlled, proof-of-concept study is to test
      the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning.
      On three days over not more than two weeks, subjects will be trained to associate cues with
      two different stimuli, then this association will be extinguished. Cannabinoid receptor
      stimulation will be accomplished both directly by administering the exogenous cannabinoid
      Δ9-tetrahydrocannabinol (THC) and indirectly by harnessing the brain's capacity to
      endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents
      degradation of anandamide. Subjects will receive placebo, Δ9-tetrahydrocannabinol (THC) or
      the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to
      preserve the study design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Startle Probe</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Galvanic skin response</measure>
    <time_frame>Test days #1, #2, and #3, on average a week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of sympathetic autonomic activation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Fear Conditioning</condition>
  <arm_group>
    <arm_group_label>Delta-9-THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delta-9-THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta-9-THC</intervention_name>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
    <arm_group_label>Delta-9-THC</arm_group_label>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04457845</intervention_name>
    <description>Acquisition of conditioning Administration of drug Extinction of conditioning</description>
    <arm_group_label>Delta-9-THC</arm_group_label>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acquisition of conditioning Administration of placebo Extinction of conditioning</description>
    <arm_group_label>Delta-9-THC</arm_group_label>
    <arm_group_label>PF-04457845</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have used cannabis at least once in their lifetime

        Exclusion Criteria:

          -  Hearing problems

          -  Psychiatric or mental problems
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohini Ranganathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence V Rispoli, BA</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>2526</phone_ext>
    <email>lawrence.rispoli@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence V. Rispoli, B.A.</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>2526</phone_ext>
      <email>lawrence.rispoli@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Mohini Ranganathan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mohini Ranganathan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fear conditioning</keyword>
  <keyword>Cannabinoids</keyword>
  <keyword>Extinction learning</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
